July 11th Options Now Available For Regeneron Pharmaceuticals (REGN)

Analysis of Regeneron Pharmaceuticals (REGN) options reveals potential strategies for investors. Selling a $590 put offers a 4.54% return (38.56% annualized) if it expires worthless, with a 55% probability based on current analytics. A covered call strategy using the $610 call yields 6.96% if the stock is called away or a 4.61% boost (39.17% annualized) if it expires worthless, with a 53% probability; implied volatilities for the put and call are 41% and 47% respectively, versus a trailing twelve-month volatility of 33%.

Analysis

The analysis focuses on options strategies for Regeneron Pharmaceuticals (REGN), currently trading at $596.00 per share. Selling a put contract at the $590.00 strike price, with a bid of $26.80, offers a potential entry point at an effective cost basis of $563.20 if assigned. This strike is approximately 1% out-of-the-money, and current analytics suggest a 55% probability of it expiring worthless, which would result in a 4.54% return on the cash commitment, or a 38.56% annualized YieldBoost. On the call side, selling a covered call at the $610.00 strike, with a bid of $27.50, against shares purchased at $596.00, could yield a total return of 6.96% if the stock is called away by the July 11th expiration. This strike is about 2% out-of-the-money, and there's a 53% assessed probability of it expiring worthless, leading to a 4.61% premium collection (39.17% annualized YieldBoost) while retaining the shares. Notably, the implied volatility for the put is 41% and for the call is 47%, both significantly higher than REGN's actual trailing twelve-month volatility of 33%, suggesting that current option premiums may be relatively rich compared to recent historical price behavior.

Key Decisions for Investors

• Investors interested in acquiring REGN shares at a discount to the current market price might consider selling the $590 strike put, aiming for an effective cost basis of $563.20 or collecting the 4.54% premium if the option expires worthless.
• Existing REGN shareholders could evaluate selling the $610 strike covered call to generate income, which offers a potential 6.96% return if called or a 4.61% yield enhancement if the option expires out-of-the-money, but this strategy caps upside potential beyond $610.
• Given that implied volatilities (41% for puts, 47% for calls) are substantially above REGN's trailing twelve-month actual volatility (33%), option sellers may find current premiums attractive, though this also reflects market expectations of increased future price movement.
• Before implementing these options strategies, a thorough review of Regeneron's business fundamentals and individual risk tolerance is essential, as upside potential can be limited or losses incurred depending on stock price movements relative to strike prices.